Precision for Medicine Acquires ACT Oncology         

Leveraging Our Expertise

ACT Oncology is currently managing clinical and data operations for a personalized medicine initiative with the Multiple Myeloma Research Foundation (MMRF) which links research, clinical and community activities to move toward tailored therapeutic approaches.   In the attempt to bring personalized treatment to multiple myeloma patients, the MMRF began its CoMMpass study (relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile) in 2011.   This is a landmark longitudinal observational study designed to uncover the molecular segments and variations in multiple myeloma.  The study looks at newly diagnosed patients with multiple myeloma and collects and analyzes tissue samples and genetic information at baseline (prior to start of treatment) and at both relapse/progression as well as suspected CR over a period of 5 years to identify insights on a personalized medicine approach to therapy to help optimize new targets and treatments.   Longer-term outcomes (i.e. survival) will continue to be observed over a longer period of time (up to 10 years).  This study is making state of the art next-going basis at both community and academic centers.

ACT Oncology celebrated with the MMRF and the Multiple Myeloma community, as the target of 1,000 enrolled patients was met in September, 2015 – a very important milestone. We are excited to participate in this trial and to help advance the understanding of multiple myeloma.

We're changing our name and website to reflect our exciting new capabilities since joining Precision for Medicine. Please visit us at precisionforoncology.com to see how we’re delivering the next generation of CRO services for oncology innovators.